Clinical Trial Update: Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of activated recombinant human factor VII in patients with refractory hemorrhagic cystitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemorrhagic Cystitis

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Other Haemostasis Disorder, Haemorrhagic Cystitis | Phase 2 | Status: COMPLETED